Tumor_NN
necrosis_NN
factor_NN
alpha_NN
decreases_NNS
,_,
and_CC
interleukin-10_NN
increases_NNS
,_,
the_DT
sensitivity_NN
of_IN
human_JJ
monocytes_NNS
to_TO
dexamethasone_NN
:_:
potential_JJ
regulation_NN
of_IN
the_DT
glucocorticoid_NN
receptor_NN
._.

Resistance_NN
to_TO
glucocorticoid_NN
therapy_NN
has_VBZ
been_VBN
observed_VBN
in_IN
patients_NNS
with_IN
autoimmune\/inflammatory_JJ
diseases_NNS
and_CC
may_MD
be_VB
related_JJ
to_TO
the_DT
inflammatory_JJ
process_NN
itself_NN
._.

The_DT
aim_NN
of_IN
this_DT
study_NN
was_VBD
to_TO
examine_VB
the_DT
ability_NN
of_IN
tumor_NN
necrosis_NN
factor_NN
alpha_NN
-LRB-_-LRB-
TNFalpha_NN
,_,
a_DT
proinflammatory_JJ
cytokine_NN
-RRB-_-RRB-
and_CC
interleukin_NN
-LRB-_-LRB-
IL_NN
-RRB-_-RRB-
-10_CD
-LRB-_-LRB-
an_DT
anti-inflammatory_JJ
cytokine_NN
-RRB-_-RRB-
to_TO
differentially_RB
regulate_VB
the_DT
sensitivity_NN
of_IN
human_JJ
monocytes\/macrophages_NNS
to_TO
glucocorticoids_NNS
._.

To_TO
accomplish_VB
this_DT
,_,
we_PRP
first_RB
analyzed_VBD
the_DT
pattern_NN
of_IN
TNFalpha_NN
and_CC
IL-10_NN
inhibition_NN
by_IN
dexamethasone_NN
in_IN
LPS-stimulated_JJ
whole-blood_JJ
cell_NN
cultures_NNS
._.

Second_RB
,_,
we_PRP
studied_VBD
the_DT
modulation_NN
of_IN
the_DT
sensitivity_NN
of_IN
these_DT
cells_NNS
to_TO
dexamethasone_NN
by_IN
preincubation_NN
with_IN
TNFalpha_NN
or_CC
IL-10_NN
and_CC
measurement_NN
of_IN
LPS-stimulated_JJ
IL-6_NN
secretion_NN
._.

In_IN
addition_NN
,_,
we_PRP
evaluated_VBD
the_DT
effect_NN
of_IN
dexamethasone_NN
on_IN
phorbolmyristate-acetate-stimulated_JJ
IL-1_NN
receptor_NN
antagonist_NN
secretion_NN
by_IN
the_DT
human_JJ
monocytic_JJ
cell_NN
line_NN
U937_NN
._.

Finally_RB
,_,
we_PRP
investigated_VBD
whether_IN
the_DT
modulation_NN
of_IN
corticosensitivity_NN
in_IN
TNFalpha_NN
-_:
and_CC
IL-10-pretreated_JJ
U937_NN
cells_NNS
was_VBD
related_JJ
to_TO
a_DT
change_NN
of_IN
the_DT
glucocorticoid_NN
receptor_NN
concentration_NN
and_CC
affinity_NN
._.

Dexamethasone_NN
had_VBD
different_JJ
effects_NNS
on_IN
LPS-induced_JJ
TNFalpha_NN
and_CC
IL-10_NN
secretion_NN
;_:
whereas_IN
it_PRP
suppressed_VBD
TNFalpha_NN
in_IN
a_DT
dose-dependent_JJ
fashion_NN
,_,
its_PRP$
effect_NN
on_IN
IL-10_NN
secretion_NN
was_VBD
biphasic_JJ
,_,
producing_VBG
stimulation_NN
at_IN
lower_JJR
,_,
and_CC
inhibition_NN
at_IN
higher_JJR
doses_NNS
._.

The_DT
concentration_NN
of_IN
LPS_NN
employed_VBN
influenced_VBD
the_DT
effect_NN
of_IN
dexamethasone_NN
on_IN
IL-10_NN
secretion_NN
-LRB-_-LRB-
P_NN
&lt;_JJR
0.001_CD
-RRB-_-RRB-
._.

Pretreatment_NN
with_IN
TNFalpha_NN
diminished_VBD
,_,
and_CC
with_IN
IL-10_NN
improved_VBN
,_,
the_DT
ability_NN
of_IN
dexamethasone_NN
to_TO
suppress_VB
IL-6_NN
secretion_NN
in_IN
whole-blood_JJ
cell_NN
cultures_NNS
-LRB-_-LRB-
P_NN
&lt;_JJR
0.01_CD
for_IN
both_DT
-RRB-_-RRB-
and_CC
to_TO
enhance_VB
IL-1_NN
receptor_NN
antagonist_NN
secretion_NN
by_IN
U937_NN
cells_NNS
-LRB-_-LRB-
P_NN
&lt;_JJR
0.05_CD
for_IN
both_DT
-RRB-_-RRB-
._.

TNFalpha_NN
decreased_VBD
-LRB-_-LRB-
P_NN
&lt;_JJR
0.001_CD
-RRB-_-RRB-
,_,
while_IN
IL-10_NN
increased_VBD
-LRB-_-LRB-
P_NN
&lt;_JJR
0.001_CD
-RRB-_-RRB-
,_,
the_DT
concentration_NN
of_IN
dexamethasone_NN
binding_NN
sites_NNS
in_IN
these_DT
cells_NNS
,_,
with_IN
no_DT
discernible_JJ
effect_NN
on_IN
their_PRP$
binding_VBG
affinity_NN
._.

We_PRP
conclude_VBP
that_IN
glucocorticoids_NNS
differentially_RB
modulate_VBP
TNFalpha_NN
and_CC
IL-10_NN
secretion_NN
by_IN
human_JJ
monocytes_NNS
in_IN
a_DT
LPS_NN
dose-dependent_JJ
fashion_NN
and_CC
that_IN
the_DT
sensitivity_NN
of_IN
these_DT
cells_NNS
to_TO
glucocorticoids_NNS
is_VBZ
altered_VBN
by_IN
TNFalpha_NN
or_CC
IL-10_NN
pretreatment_NN
;_:
TNFalpha_NN
blocks_VBZ
their_PRP$
effects_NNS
,_,
whereas_IN
IL-10_NN
acts_VBZ
synergistically_RB
with_IN
glucocorticoids_NNS
._.

This_DT
is_VBZ
accompanied_VBN
by_IN
opposite_JJ
glucocorticoid_NN
receptor_NN
changes_NNS
,_,
respectively_RB
opposing_VBG
and_CC
favoring_VBG
glucocorticoid_NN
actions_NNS
._.

This_DT
study_NN
suggests_VBZ
that_IN
the_DT
pattern_NN
of_IN
pro-_JJ
\/_CC
antiinflammatory_JJ
cytokine_NN
secretion_NN
may_MD
alter_VB
the_DT
response_NN
of_IN
patients_NNS
to_TO
glucocorticoid_NN
therapy_NN
._.

